Discovery of MCM2-7 complex is new therapeutic target for neuroendocrine prostate cancer

June 25, 2021

Exiting new study from our lab identifies MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. Congratulations En-chi and team!

https://www.nature.com/articles/s41598-021-92552-x

June 25, 2021

News Stanford

PreviousExciting news: Dr. Busola Alabi joins Stoyanova lab!
NextDevelopment of a new method for the quantification of cancer invasion and migration ability

Exciting News: Diana Argiles Castillo passed her qualifying examination and is now a PhD candidate

News

Exciting news: Dr. Shiqin (Laura) Liu awarded grant from Department of Defense to develop immunotherapy for neuroendocrine prostate cancer.

News

Discovery of MCM2-7 complex is new therapeutic target for neuroendocrine prostate cancer

PreviousExciting news: Dr. Busola Alabi joins Stoyanova lab!

NextDevelopment of a new method for the quantification of cancer invasion and migration ability

Related Posts ...

Exciting News: Diana Argiles Castillo passed her qualifying examination and is now a PhD candidate

Exciting news: Dr. Shiqin (Laura) Liu awarded grant from Department of Defense to develop immunotherapy for neuroendocrine prostate cancer.